Methylxanthines: Potential Therapeutic Agents for Glioblastoma
Open Access
- 7 September 2019
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 12 (3) , 130
Abstract
Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Currently, treatment is ineffective and the median overall survival is 20.9 months. The poor prognosis of GBM is a consequence of several altered signaling pathways that favor the proliferation and survival of neoplastic cells. One of these pathways is the deregulation of phosphodiesterases (PDEs). These enzymes participate in the development of GBM and may have value as therapeutic targets to treat GBM. Methylxanthines (MXTs) such as caffeine, theophylline, and theobromine are PDE inhibitors and constitute a promising therapeutic anti-cancer agent against GBM. MTXs also regulate various cell processes such as proliferation, migration, cell death, and differentiation; these processes are related to cancer progression, making MXTs potential therapeutic agents in GBM.Keywords
This publication has 101 references indexed in Scilit:
- Adenosine receptors as drug targets — what are the challenges?Nature Reviews Drug Discovery, 2013
- TheophyllinePharmaceuticals, 2010
- Caffeine-Mediated Inhibition of Calcium Release Channel Inositol 1,4,5-Trisphosphate Receptor Subtype 3 Blocks Glioblastoma Invasion and Extends SurvivalCancer Research, 2010
- Adenosine Receptors and Cancer2009
- High-Resolution Genomic Copy Number Profiling of Glioblastoma Multiforme by Single Nucleotide Polymorphism DNA MicroarrayMolecular Cancer Research, 2009
- Cyclic nucleotide phosphodiesterase profiling reveals increased expression of phosphodiesterase 7B in chronic lymphocytic leukemiaProceedings of the National Academy of Sciences, 2008
- Targeted Inhibition of Cyclic AMP Phosphodiesterase-4 Promotes Brain Tumor RegressionClinical Cancer Research, 2008
- Theophylline in Chronic Obstructive Pulmonary Disease: New HorizonsProceedings of the American Thoracic Society, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Isolation and Characterization of cDNAs Corresponding to Two Human Calcium, Calmodulin-regulated, 3′,5′-Cyclic Nucleotide PhosphodiesterasesJournal of Biological Chemistry, 1996